Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
CSTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.59 - $35.84
Previous CloseN/A
Volume108.23K
Average Volume (3M)478.76K
Market Cap
$561.02M
Enterprise Value$364.73M
Total Cash (Recent Filing)$275.93M
Total Debt (Recent Filing)$37.35M
Price to Earnings (P/E)30.6
Beta1.12
Next Earnings
Nov 10, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding29,008,282
10 Day Avg. Volume748,432
30 Day Avg. Volume478,761
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)1.62
Price to Sales (P/S)2.23
P/FCF Ratio20.26
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda14.57
Forecast
1Y Price Target
$34.07Price Target Upside75.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PositionCSTL shares trade at a significantly lower valuation compared to its clinical peers, suggesting potential undervaluation.
Product PerformanceTissueCypher is the main growth driver for CSTL, with volumes 25% above consensus expectations.
Strategic CollaborationCastle Biosciences enters a collaboration and license agreement with SciBase Holding AB to develop a diagnostic test for atopic dermatitis.
Bears Say
Reimbursement UncertaintyThere is uncertainty regarding the SCC reimbursement status, which could impact CSTL's profitability.
Revenue ChallengesCSTL will no longer benefit from DDx-SCC revenue.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $561.02M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Nov 10, 2025 which is in 87 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Aug 04, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.681.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.53.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 29,008,282 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went up 32.833%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.07 (75.53% Upside)
$34.07 (75.53% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 34.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.70%
12-Months-Change
Fundamentals
Return on Equity
-2.15%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Castle Biosciences demonstrated strong growth in test volumes and revenue, particularly with the TissueCypher and DecisionDx-Melanoma tests. However, reimbursement challenges with the DecisionDx-SCC test and increased operating expenses impacted financial results. Despite these challenges, the company raised its revenue guidance and maintains a strong financial position.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$34.07
▲(75.53% Upside)
Technical Analysis
Ownership Overview
2.68% Insiders
27.23% Mutual Funds
0.18% Other Institutional Investors
55.51% Public Companies and
Individual Investors